Marion Lanteri | Global Scientific Affairs Director | Cerus Global Headquarters
3:10 – 3:35 pm
Merits and pitfalls of automated bacterial culture methods in improving bacterial safety of platelet concentrates
Sandra Ramirez-Arcos | Senior Scientist, Canadian Blood Services and Adjunct Professor, University of Ottawa | Ottawa, Canada
What are the merits of automated bacterial culture methods? Despite of almost three decades of routine use, variability of platelet storage times and screening protocols by different blood suppliers reflect the absence of a gold standard protocol for bacterial detection. What is the impact of those variables on the bacterial safety of platelet concentrates and are there any other pitfalls we need to be aware of?
3:35 - 4:00 pm
Reduction in the risk of bacterial contamination, platelet components prepared with Amotosalen-UVA photochemical treatment. What can we conclude after 15 years of routine experience?
Laurence Corash | Chief Scientific Officer | Cerus Global Headquarters
Pathogen inactivation is being increasingly used to improve the safety of blood transfusion.
But what is its track-record in improving bacterial safety of platelet concentrates? Which scientific evidence has been published and what can we conclude after millions of routine transfusions? Define the specifications every pathogen inactivation system should meet to ensure its ability to maintain bacterial sterility of platelet concentrates until the end of storage.
Are there any pitfalls we should be aware of?
4:00 – 4:15 pm
Marion Lanteri | Scientific Affairs Director | Cerus Global Headquarters
1220 Concord Avenue
Concord, CA US 94520
3811 MH Amersfoort, Netherlands
+31 (0)33 49 60 600
Copyright 2021, CERUS. All rights reserved. MKT-EN 00477-14, v3.0
Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the US. Also in the US, the INTERCEPT Blood System for Cryoprecipitation is approved for production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex, a therapeutic product for the treatment and control of bleeding associated with fibrinogen deficiency, including massive hemorrhage. Follow us on LinkedIn.